Skip to main content
Clinical Trials/NCT04392726
NCT04392726UnknownNot Applicable

Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)

Sheba Medical Center1 site in 1 country30 target enrollmentStarted: August 1, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
30
Locations
1
Primary Endpoint
The primary outcome measure of this study is to determine the diagnostic performance of ULDCT in diagnosis of DPLD.

Study Overview

Brief Summary

The primary intention of this study is to determine the diagnostic performance of ultra-low-dose CT (ULDCT) in diagnosis and follow-up of diffuse parenchymal lung disease (DPLD). We hypothesize that inspiratory and expiratory chest ULDCT has comparable diagnostic yield to standard dose chest High-resolution computed tomography (HRCT) and utility for follow-up of patients with known DPLD. We will study this hypothesis through the following aims:

  1. Determine whether inspiratory and expiratory ULDCT are comparable to HRCT in identifying mosaic attenuation due to air-trapping.
  2. Determine whether ULDCT is as good as HRCT for follow-up of patients with established DPLD to identify disease progression.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • suspected or known DPLD
  • referred to DPLD observation

Exclusion Criteria

  • other lung related diseases

Outcomes

Primary Outcomes

The primary outcome measure of this study is to determine the diagnostic performance of ULDCT in diagnosis of DPLD.

Time Frame: during the procedure/surgery

The diagnostic performance will be evaluated according to the biopsy results

The primary outcome measure of this study is to determine the prognostic performance of ULDCT in the follow up of DPLD.

Time Frame: during the procedure/surgery

The diagnostic performance will be evaluated according to the biopsy results

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other Gov
Responsible Party
Principal Investigator
Principal Investigator

Dr. Liran Levy

Transplant pulmonologist

Sheba Medical Center

Study Sites (1)

Loading locations...

Similar Trials